Effects of zoledronic acid in different time periods in the treatment of elderly osteoporotic vertebral compression fractures after percutaneous kyphoplasty
-
摘要:目的 探讨经皮椎体后凸形成术(PKP)后不同时机应用唑来膦酸治疗老年骨质疏松性椎体压缩骨折(OVCFs)的临床疗效。方法 将80例老年OVCFs患者按随机数字表法分为观察组和对照组,每组40例。2组均行PKP,观察组术后第3天静脉滴注唑来膦酸,对照组术后1月使用唑来膦酸。比较2组术前、术后伤椎椎体高度、局部椎体后凸Cobb角变化、视觉模拟评分法(VAS)评分、Oswestry功能障碍指数(ODI)、腰椎及髋部骨密度(BMD);检测2组骨转换生化指标(BTMS),包括Ⅰ型前胶原氨基端前肽(PINP)、β-Ⅰ型胶原C-末端肽交联(β-CTX);记录2组椎体压缩骨折再发生情况及不良反应发生情况。结果 术后1、3个月,观察组VAS、ODI评分低于对照组,差异有统计学意义(P < 0.05);术后6个月及术后1年,观察组腰椎及髋部BMD T值高于对照组,PINP、β-CTX低于对照组,差异有统计学意义(P < 0.05)。结论 老年OVCFs患者行PKP后尽早使用唑来膦酸,可减轻疼痛,恢复椎体高度及校正后凸角度,且在提高骨密度、改善骨代谢方面更具优势。
-
关键词:
- 唑来膦酸 /
- 经皮椎体后凸成形术 /
- 骨质疏松性椎体压缩性骨折 /
- 老年 /
- 骨密度
Abstract:Objective To investigate the clinical effects of zoledronic acid in different time periods in the treatment of elderly osteoporotic vertebral compression fractures (OVCFs) after percutaneous kyphoplasty (PKP).Methods Eighty elderly patients with OVCFs were divided into observation group and control group according to random number table method, with 40 cases in each group. Both groups received PKP, the observation group received intravenous infusion of zoledronic acid on the 3rd day after surgery, and the control group received zoledronic acid 1 month after surgery. The height of the injured vertebrae, the change of the Cobb angle of the local vertebrae, the Visual Analogue Scale (VAS) score, the Oswestry disability index (ODI), the bone mineral density (BMD) of the lumbar spine and hip were compared between the two groups before and after surgery. Bone transformation biochemical markers (BTMS) were detected in the two groups, including N-terminal propeptide of typeⅠprocollagen (PINP) and β cross-linked C-telopeptide of typeⅠcollagen (β-CTX). Recurrence of vertebral compression fractures and adverse reactions were recorded in the two groups.Results At 1 month and 3 months after operation, the VAS and ODI scores of the observation group were significantly lower than those of the control group (P < 0.05); At 6 months and 1 year after surgery, the BMD T values of lumbar spine and hip in observation group were significantly higher, PINP and β-CTX were significantly lower than those in the control group (P < 0.05).Conclusion Early use of zoledronic acid after PKP in elderly OVCFs patients can reduce pain, restore vertebral height and correct kyphosis angle, and have advantages in improving bone mineral density and bone metabolism. -
-
表 1 2组术前一般资料比较(x±s)
一般资料 观察组(n=40) 对照组(n=40) t/χ2 P 性别 男 18 16 0.205 0.651 女 22 24 年龄/岁 66.43±3.25 66.53±3.79 -0.127 0.900 病程/d 4.82±1.59 4.40±1.63 1.161 0.249 骨折部位 T6~T9 4 5 0.257 0.879 T10~L2 30 28 L3~L5 6 7 甲状旁腺素/(pg/mL) 61.17±17.83 60.24±17.90 0.233 0.817 血清25-羟基维生素D/(ng/mL) 14.81±3.23 14.96±3.27 -0.204 0.839 空腹血糖/(mmol/L) 4.48±1.05 4.30±1.35 0.661 0.511 表 2 2组术前、术后VAS评分比较(x±s)
分 组别 n 术前 术后1个月 术后3个月 术后6个月 术后1年 观察组 40 7.78±1.12 3.48±0.75*# 2.37±0.49*# 2.15±0.58* 2.20±0.65* 对照组 40 7.60±1.10 4.53±1.13* 3.10±0.67* 2.28±0.68* 2.40±0.63* VAS: 视觉模拟评分法。与术前比较, * P < 0.05; 与对照组比较, #P < 0.05。 表 3 2组ODI评分比较(x±s)
分 组别 n 术前 术后1个月 术后3个月 术后6个月 术后1年 观察组 40 37.55±5.14 21.23±3.01*# 19.05±2.88*# 19.28±2.75* 20.55±3.27* 对照组 40 37.28±4.68 29.20±3.45* 24.23±2.78* 20.13±2.49* 20.93±2.68* ODI: Oswestry功能障碍指数。与术前比较, *P < 0.05; 与对照组比较, #P < 0.05。 表 4 2组伤椎椎体高度比较(x±s)
mm 组别 n 术前 术后1个月 术后3个月 术后6个月 术后1年 观察组 40 16.50±1.85 24.70±2.95* 24.90±2.70* 23.65±2.26* 23.28±2.86* 对照组 40 16.83±1.72 24.53±2.62* 24.18±3.15* 23.30±2.26* 23.18±2.97* 与术前比较, * P < 0.05。 表 5 2组局部椎体后凸Cobb角比较(x±s)
° 组别 n 术前 术后1个月 术后3个月 术后6个月 术后1年 观察组 40 25.30±5.81 17.05±2.95* 14.30±2.80* 11.45±2.33* 9.88±2.28* 对照组 40 23.75±6.56 17.63±2.57* 14.50±2.73* 12.20±1.98* 10.18±2.22* 与术前比较, * P < 0.05。 表 6 2组腰椎及髋部BMD T值比较(x±s)
组别 n 腰椎 髋部 术前 术后6个月 术后1年 术前 术后6个月 术后1年 观察组 40 -3.56±0.28 -2.61±0.23*# -1.80±0.36*# -3.84±0.29 -2.48±0.26*# -1.97±0.26*# 对照组 40 -3.57±0.22 -2.84±0.24* -2.05±0.33* -3.87±0.31 -2.69±0.30* -2.38±0.24* BMD: 骨密度。与术前比较, * P < 0.05; 与对照组比较, #P < 0.05。 表 7 2组术前、术后PINP、β-CTX比较(x±s)
μg/L 组别 n PINP β-CTX 术前 术后6个月 术后1年 术前 术后6个月 术后1年 观察组 40 56.03±6.69 44.56±5.59*# 32.65±2.72*# 0.88±0.20 0.47±0.20*# 0.21±0.09*# 对照组 40 57.19±5.19 47.91±5.89* 38.63±3.07* 0.85±0.21 0.67±0.15* 0.31±0.10* PINP: Ⅰ型前胶原氨基端前肽; β-CTX: β-Ⅰ型胶原C-末端肽交联。与术前比较, * P < 0.05; 与对照组比较, #P < 0.05。 -
[1] 王复案, 陈允震. 骨质疏松性椎体压缩性骨折诊疗现状及其对策[J]. 中国骨质疏松杂志, 2019, 25(5): 590-594, 599. doi: 10.3969/j.issn.1006-7108.2019.05.004 [2] 中华医学会骨科学分会. 骨质疏松骨折诊疗指南[J]. 中国骨肿瘤骨病, 2009, 8(5): 287-291. doi: 10.3969/j.issn.1671-1971.2009.10.011 [3] LIN X, XIONG D, PENG Y Q, et al. Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives[J]. Clin Interv Aging, 2015, 10: 1017-1033. http://pubmedcentralcanada.ca/pmcc/articles/PMC4485798/
[4] WANG O, HU Y, GONG S, et al. A survey of outcomes and management of patients post fragility fractures in China[J]. Osteoporos Int, 2015, 26(11): 2631-2640. doi: 10.1007/s00198-015-3162-6
[5] BOUZA C, LÓPEZ-CUADRADO T, ALMENDRO N, et al. Safety of balloon kyphoplasty in the treatment of osteoporotic vertebral compression fractures in Europe: a meta-analysis of randomized controlled trials[J]. Eur Spine J, 2015, 24(4): 715-723. http://smartsearch.nstl.gov.cn/paper_detail.html?id=b665650ca9ea3bce11e39f8f81e60e0b
[6] 柯呈辉, 何立江, 吴文华. 双膦酸盐防治骨质疏松性骨折的研究进展[J]. 中国骨质疏松杂志, 2019, 25(6): 870-874. doi: 10.3969/j.issn.1006-7108.2019.06.030 [7] 李荣锐, 王天枢, 魏巍, 等. 农村地区老年人骨质疏松患病率及影响因素[J]. 中国老年学杂志, 2018, 38(14): 3534-3537. doi: 10.3969/j.issn.1005-9202.2018.14.080 [8] 丁悦, 张嘉, 岳华, 等. 骨质疏松性椎体压缩性骨折诊疗与管理专家共识[J]. 中华骨质疏松和骨矿盐疾病杂志, 2018, 11(5): 425-437. doi: 10.3969/j.issn.1674-2591.2018.05.001 [9] YI X D, LU H L, TIAN F, et al. Recompression in new levels after percutaneous vertebroplasty and kyphoplasty compared with conservative treatment[J]. Arch Orthop Trauma Surg, 2014, 134(1): 21-30. doi: 10.1007/s00402-013-1886-3
[10] 叶向阳, 汤立新, 程省, 等. 骨密度对骨质疏松性椎体压缩性骨折PKP术后骨折再发风险的评估价值[J]. 中国骨质疏松杂志, 2017, 23(2): 154-158. doi: 10.3969/j.issn.1006-7108.2017.02.004 [11] BYUN J H, JANG S, LEE S, et al. The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis[J]. J Bone Metab, 2017, 24(1): 37-49. doi: 10.11005/jbm.2017.24.1.37
[12] 李凯明, 朱立国, 张清, 等. 唑来膦酸联合椎体后凸成形治疗骨质疏松性压缩骨折: 提高骨密度、预防椎体再骨折、远期疗效评价的meta分析[J]. 中国组织工程研究, 2020, 24(24): 3911-3917. doi: 10.3969/j.issn.2095-4344.2721 [13] MORIWAKI K, MOURI M, HAGINO H. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan[J]. Osteoporos Int, 2017, 28(6): 1939-1950. doi: 10.1007/s00198-017-3973-8
[14] AMANAT N, MCDONALD M, GODFREY C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair[J]. J Bone Miner Res, 2007, 22(6): 867-876. doi: 10.1359/jbmr.070318
[15] ERIKSEN E F, LYLES K W, COLÓN-EMERIC C S, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture[J]. J Bone Miner Res, 2009, 24(7): 1308-1313. doi: 10.1359/jbmr.090209
[16] LI Y T, CAI H F, ZHANG Z L. Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials[J]. Osteoporos Int, 2015, 26(2): 431-441. doi: 10.1007/s00198-014-2903-2
[17] 李季, 赵维彪, 何子微, 等. 经皮穿刺椎体成形同期与非同期联合唑来膦酸治疗骨质疏松性椎体压缩骨折的1年随访比较[J]. 中国组织工程研究, 2018, 22(30): 4788-4793. doi: 10.3969/j.issn.2095-4344.0980 [18] SOLOMON D H, HOCHBERG M C, MOGUN H, et al. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults[J]. Osteoporos Int, 2009, 20(6): 895-901. doi: 10.1007/s00198-008-0759-z
-
期刊类型引用(14)
1. 汤骏姣. 对接受内镜下止血治疗的消化道出血患者进行时间护理的效果分析. 当代医药论丛. 2020(02): 257-259 . 百度学术
2. 裴艳苓. 时间护理对消化道出血患者止血的效果及健康知识指标的影响评价. 中国医药指南. 2020(08): 288-289 . 百度学术
3. 刘洁羽. 优质护理模式对上消化道出血患者康复质量及满意度的影响. 辽宁医学杂志. 2020(02): 81-83 . 百度学术
4. 王英姿. 个体化系统护理在上消化道出血急救中的应用效果. 黑龙江中医药. 2020(01): 268-269 . 百度学术
5. 张艳. 针对性预防护理在消化道出血患者中的应用效果. 中国当代医药. 2019(02): 245-247 . 百度学术
6. 刘坤. 时间护理对消化道出血患者止血的效果及健康知识的价值体会. 世界最新医学信息文摘. 2019(17): 285-286 . 百度学术
7. 李闻新, 张余, 部实, 张雪柏, 闫宇青, 张福林, 卢占斌. 3种质子泵抑制药预防颈脊髓损伤患者应激性溃疡的最小成本分析. 中国药师. 2019(05): 870-872 . 百度学术
8. 缪君芳. 时间护理联合常规护理在脑梗塞患者中的护理效果观察. 智慧健康. 2019(32): 135-136 . 百度学术
9. 汤天娟. 时间护理对消化道出血患者止血的效果及健康知识指标的影响评价. 中西医结合心血管病电子杂志. 2019(32): 113-114 . 百度学术
10. 李韦韦, 楚建杰, 胡冬梅, 赵先, 王婧雯. 某院国产和进口奥曲肽治疗上消化道出血的成本-效果分析. 中国医院药学杂志. 2018(04): 440-442+449 . 百度学术
11. 高媛媛, 李新萍, 连凯敏. 消化道出血患者的临床观察及护理要点探究. 中国农村卫生. 2018(17): 55+57 . 百度学术
12. 邵菊香. 时间护理对肝硬化合并消化道出血患者止血的效果及健康知识的影响效果分析. 中国农村卫生. 2018(24): 57-58 . 百度学术
13. 刘晓霞. 68例上消化道出血患者的临床观察及护理. 世界最新医学信息文摘. 2017(55): 183+191 . 百度学术
14. 颜爱丽. 时间护理对消化道出血患者止血的效果及健康知识的影响研究. 现代医学与健康研究电子杂志. 2017(09): 111 . 百度学术
其他类型引用(1)
计量
- 文章访问数: 321
- HTML全文浏览量: 179
- PDF下载量: 11
- 被引次数: 15